Dr. Douglas Harrington, CEO Of Aviir, Speaks At The Healthy Living Festival On Heart Disease And The Dangers Of Vulnerable Plaque

IRVINE, Calif., Oct. 12, 2012 /PRNewswire/ -- Aviir Inc., a biotechnology company dedicated to the prevention of cardiovascular disease through innovative laboratory tests, announced today that Dr. Douglas Harrington, CEO of Aviir will be speaking at the Healthy Living Expo at the Del Mar Fairgrounds.  Dr. Harrington will speak on Saturday, October 13th at noon PST on the topic of cardiovascular risk assessment and Aviir's laboratory tests which are targeted at encouraging individual cardiac disease prevention.

Dr. Harrington will also appear on a live TV segment with NBC San Diego on Friday October 12 at 11:30am PST.  The NBC segment will promote the Healthy Living Festival and also features Dr. Harrington's speaking session at the festival on heart disease prevention.

"Heart Disease remains the nation's #1 killer and a major cause of disability and bankruptcy," commented Dr. Douglas Harrington. "Fortunately it is largely preventable through lifestyle modification, which can reduce an individual's risk by as much as 80%. "  Dr. Harrington will discuss an innovative blood test, developed through an Aviir/Stanford University cardiology collaboration, which identifies an individuals' cardiac risk in a five-year timeframe. "This timeframe allows preventive measures to be implemented," continued Dr. Harrington. "Our mission is to improve healthcare and encourage timely preventive strategies by providing this unique medical information."

About Aviir

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients that are truly at high risk for the development of a cardiac event.  Aviir's proprietary MIRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years.  Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests. The company has adopted a unique clinical laboratory service model to provide physicians better diagnostic tools that improve cardiovascular health of their patients. The company is privately owned and funded by leading life science venture capital firms. Please visit www.aviir.com for more information.

About Healthy Living Festival
The Healthy Living Festival takes place at the Del Mar Fairgrounds with over 200 exhibitors. At this expo, experts share new ideas about lifestyle changes that may prevent disease and lower stress. The Healthy Living Festival takes place at the Del Mar Fairgrounds October 13 & 14. Festival hours Saturday are 10AM - 7PM and Sunday from 10AM - 5PM. The festival offers free workshops and seminars, medical testing, cooking demonstrations, yoga, zumba, stretch classes and belly dancing. Attendees can visit over 150 exhibitors offering the latest healthy living products and services.

For media inquiries, please contact:

Dina Scaglione
[email protected]

SOURCE Aviir Inc.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.